Biotome Heads to Boston: Meet Us at BIO 2025

Biotome will join the Australian delegation at the BIO International Convention in Boston, June 16-19, 2025. This is our first major US biotechnology conference – and we're ready to connect.

Why We're Going

Our Founder and CEO, Samuel Lundin, will be seeking partners across three key areas:

Diagnostic Companies

Ready to upgrade your serology tests? Our peptide-based platform eliminates cross-reactivity issues and cuts manufacturing costs compared to whole-protein approaches.

Vaccine Developers

Need epitope mapping? We've validated over 1,000 epitopes and can accelerate your vaccine optimisation, from protective epitope identification to clinical trial monitoring.

Strategic Partners

Looking for proven technology with global IP protection? Helitope – our gastric cancer risk diagnostic – demonstrates our ability to translate science into commercial products.

Helitope Licensing

Our lead diagnostic identifies H. pylori patients at highest cancer risk. With patents granted in 20 countries, we're exploring commercialisation partnerships for global markets. The technology's potential for population-wide screening programs could transform gastric cancer from a leading killer to a preventable disease.

Find Us in Boston

We'll be part of the Australian delegation organised by MTPConnect. While we won't have a booth, you can:

• Schedule meetings via the BIO partnering app

• Email us directly at info@biotome.com.au

• Find us at the Australian Pavilion!

What We Offer

We Make Peptide-ELISA Work

Our patent-pending peptide augmentation technology dramatically increases ELISA sensitivity – solving fundamental problems that have historically plagued peptide-based diagnostics.

Epitope Mapping Services

We've tested over 350,000 different peptides across diverse applications:

• Vaccine and therapeutic antibody development

• Identifying patentable diagnostic markers

• Autoimmune disease target identification

• and more!

Complete Diagnostic Pipeline

From epitope discovery to ready-for-manufacture prototypes, we handle the entire development process. Our research-use-only ELISA kits provide low-cost research support and validation that your markers work in real-world conditions.

With patents in 20 countries and a proven track record of commercialisation, we bring both technical expertise and strategic IP guidance to partnerships.

Let's Connect

Whether you're developing diagnostics, optimising vaccines, or need precision antibody analysis, let's discuss how epitope-level resolution can advance your programs.

Boston awaits. See you there.

Biotome founder and CEO, Samuel Lundin

Contact Samuel Lundin (samuel.lundin@biotome.com.au) arrange a meeting at BIO 2025.